The clinical utility of circulating tumour cells in patients with small cell lung cancer

Foy, Victoria; Fernández‐Gutiérrez, Fabiola; Faivre-Finn, Corinne; Dive, Caroline; Blackhall, Fiona

doi:10.21037/tlcr.2017.07.05

Cited by 31 publications

(23 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serial sampling would give information on disease burden, responses to treatment and on disease relapse. Promising results have been obtained with circulating tumor cells (CTCs) [14] , but there is a large variation in CTC numbers and heterogeneity in the expression of NCAM [14] . Our present strategy is to use tumor derived extracellular vesicles (EVs) as a correlate of tumor load.…”

Section: Discussionmentioning

confidence: 99%

Monoclonal antibodies to the exon 18 encoded moiety of NCAM

Borght¹,

Duysinx²,

Ummelen³

et al. 2019

JCMT

View full text Add to dashboard Cite

Aim: Exon 18 expression of NCAM has been recognized as a biomarker for small cell lung cancer (SCLC). To use this finding for an improved diagnosis of SCLC and personalized treatment of patients, techniques to identify and quantitate E18, the exon 18 encoded protein moiety of NCAM, are needed. We developed three monoclonal antibodies for this purpose. Methods: The his-tagged E18 antigen was expressed in E. coli and, after purification, used to immunize mice. Hybridoma's were isolated by standard procedures and tested for their reaction with E18. Results: Three monoclonal antibodies, MUM-1, MUM-4 and MUM-6 were obtained. They reacted with E18 in western blots, with SCLC cell line NCI-H82, but not with unrelated his-tagged proteins. Only permeabilized NCI-H82 cells stained with the antibodies, confirming the intracellular position of E18. Next an enzyme-linked immunosorbent assay was developed using the earlier isolated monoclonal antibody MUMi-21B2, coated on the surface of microtiter wells as capture antibody and biotinylated MUM-6 as second antibody. Using streptavidin conjugated to horse radish peroxidase a linear dose response curve to his-tagged E18 antigen was obtained between 0 and 5 µg/mL with a sensitivity of at least 0.5 µg/mL or 50 ng/well. Conclusion: Four monoclonal antibodies are available to be used in assays for the identification and quantification of SCLC biomarker E18. This will enable the development of liquid biopsies to follow the tumor load in patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Monoclonal antibodies to the exon 18 encoded moiety of NCAM

Borght¹,

Duysinx²,

Ummelen³

et al. 2019

JCMT

View full text Add to dashboard Cite

show abstract

“…CTCs play a relevant role in small cell lung cancer (SCLC). In particular, CTCs were detectable in about 70–95% of patients with SCLC [40, 41]. The identification of CTCs may play an important role in the early detection of SCLC [40].…”

Section: Circulating Tumour Cellsmentioning

confidence: 99%

“…In particular, CTCs were detectable in about 70–95% of patients with SCLC [40, 41]. The identification of CTCs may play an important role in the early detection of SCLC [40]. In the experience by Ilie et al [42], the authors showed that all patients with the identification of CTCs developed a pulmonary nodule during the follow-up and before CT identification.…”

Section: Circulating Tumour Cellsmentioning

confidence: 99%

“…In the experience by Ilie et al [42], the authors showed that all patients with the identification of CTCs developed a pulmonary nodule during the follow-up and before CT identification. A high level of CTCs in SCLC patients correlates with the worst prognosis [40]. In a study by Hou et al [43], a high number of CTCs (> 300) was associated with a significant reduction of survival compared to patients with a low number of CTCs detected (< 2).…”

Section: Circulating Tumour Cellsmentioning

confidence: 99%

“…In a study by Hou et al [43], a high number of CTCs (> 300) was associated with a significant reduction of survival compared to patients with a low number of CTCs detected (< 2). Another important role of CTCs in these patients was represented by the possibility of a molecular characterisation of CTCs that can provide relevant clinical information [40]. Pore et al [44] demonstrated the possibility that there was a relationship between the number of CTCs and overall survival rate, correlated to the presence of cancer stem cell (CSC) markers and mesenchymal markers in tumour biopsy samples.…”

Section: Circulating Tumour Cellsmentioning

confidence: 99%

See 2 more Smart Citations

Circulating Tumour Cells in Predictive Molecular Pathology: Focus on Drug-Sensitive Assays and 3D Culture

et al. 2019

View full text Add to dashboard Cite

Molecular cytopathology is a rapidly evolving field of cytopathology that provides biological information about the response to personalised therapy and about the prognosis of neoplasms diagnosed on cytological samples. Biomarkers such as circulating tumour cells and circulating tumour DNA are increasingly being evaluated in blood and in other body fluids. Such liquid biopsies are non-invasive, repeatable, and feasible also in patients with severe comorbidities. However, liquid biopsy may be challenging due to a low concentration of biomarkers. In such cases, biomarkers can be detected with highly sensitive molecular techniques, which in turn should be validated and integrated in a complex algorithm that includes tissue-based molecular assessments. The aim of this review is to provide the cytopathologist with practical information that is relevant to daily practice, particularly regarding the emerging role of circulating tumour cells in the field of predictive molecular pathology.

show abstract

Circulating tumor cell profiling for precision oncology

Labib

2021

Molecular Oncology

View full text Add to dashboard Cite

Analysis of circulating tumor cells (CTCs) collected from patient's blood offers a broad range of opportunities in the field of precision oncology. With new advances in profiling technology, it is now possible to demonstrate an association between the molecular profiles of CTCs and tumor response to therapy. In this Review, we discuss mechanisms of tumor resistance to therapy and their link to phenotypic and genotypic properties of CTCs. We summarize key technologies used to isolate and analyze CTCs and discuss recent clinical studies that examined CTCs for genomic and proteomic predictors of responsiveness to therapy. We also point out current limitations that still hamper the implementation of CTCs into clinical practice. We finally reflect on how these shortcomings can be addressed with the likely contribution of multiparametric approaches and advanced data analytics.

show abstract

The clinical utility of circulating tumour cells in patients with small cell lung cancer

Cited by 31 publications

References 55 publications

Monoclonal antibodies to the exon 18 encoded moiety of NCAM

Monoclonal antibodies to the exon 18 encoded moiety of NCAM

Circulating Tumour Cells in Predictive Molecular Pathology: Focus on Drug-Sensitive Assays and 3D Culture

Circulating tumor cell profiling for precision oncology

Contact Info

Product

Resources

About